I want all the topics discussed since 12 June and 13 June until now. Format your response so a patient skimming on...

TL;DR:

Since June 12-13, we've discussed your diagnosis (mesonephric-like adenocarcinoma with KRAS G12A mutation), treatment options (niraparib vs. KRAS inhibitor trials), European clinical trials available in France, and how to safely start niraparib while managing summer travel.

---

KEY POINTS:

• Your cancer has a KRAS G12A mutation — this makes you eligible for precision medicine trials (RMC-6236, BI 1701963) that may be more effective than standard PARP inhibitors
• Niraparib is a daily pill, not an infusion — you take it at home, but need intensive blood monitoring for 4-6 weeks after starting (not safe to start while traveling)
• KRAS inhibitor trials ARE available in France and nearby Europe — at Institut Gustave Roussy, Institut Curie, and other major centers; contact trial sponsors directly to find participating sites
• You should start niraparib 2-4 weeks after chemo ends — plan your summer travel either before starting niraparib or after you've stabilized (4-6 weeks in)
• You can save this entire conversation as a PDF or Word document — useful for sharing with oncologists, clinical trial coordinators, and keeping your own [ID removed]

---

NEXT STEP:

Ask your oncologist: "Given my KRAS G12A mutation and HRD-negative status, should I pursue a KRAS inhibitor trial (RMC-6236 or BI 1701963) instead of niraparib, or can I do both? And when should I start treatment relative to my summer travel plans?"

---

---

FULL ANSWER

COMPREHENSIVE SUMMARY: JUNE 12-13 TO PRESENT

This document summarizes all major topics discussed since June 12-13, organized by theme. Use this as your reference guide for your medical decisions and conversations with your oncology team.

---

SECTION 1: YOUR DIAGNOSIS & BIOMARKERS

What We Know About Your Cancer

Cancer Type: Mesonephric-Like Adenocarcinoma (MLA)

What it is:

• A rare type of ovarian cancer (accounts for <5% of ovarian cancers)
• Arises from mesonephric remnants (embryologic tissue in the ovary)
• Behaves differently from high-grade serous carcinoma (HGSC)
• Often presents at advanced stage

Your specific diagnosis:

• Confirmed mesonephric-like adenocarcinoma
• Lesions detected by end of November (indicating advanced disease)
• Treated with HGSC protocol (carboplatin/paclitaxel + bevacizumab)

Why this matters:

• MLA is rare, so treatment recommendations are less standardized
• Your biomarkers (KRAS G12A, BRAF, HRD-negative) are more important for guiding treatment than cancer type alone
• Precision medicine (targeted therapy based on mutations) is particularly important for rare cancers

Source: NCCN Guidelines for Patients: Ovarian Cancer (2025) — discusses rare ovarian cancer types and precision medicine approach

---

Your Biomarker Profile (Critical for Treatment Decisions)

KRAS Mutation: G12A (Pathogenic)

What it means:

• Your cancer cells have a mutation in the KRAS gene at position 12, amino acid A (G12A)
• This mutation is "pathogenic" — it drives cancer growth
• KRAS mutations are found in 30-40% of ovarian cancers, but G12A is less common than G12C
• This mutation makes your cancer potentially responsive to KRAS inhibitors

Treatment implications:

• ✅ You are eligible for KRAS inhibitor trials (RMC-6236, BI 1701963, MRTX1133)
• ✅ KRAS inhibitors may be more effective than standard PARP inhibitors for your cancer
• ⚠️ KRAS inhibitors are investigational (not yet FDA-approved for ovarian cancer)
• ⚠️ You need to weigh KRAS inhibitor trial vs. standard niraparib maintenance therapy

Clinical trial options:

• RMC-6236 (Revolution Medicines) — pan-KRAS inhibitor, targets G12A specifically
• BI 1701963 (Boehringer Ingelheim) — pan-KRAS inhibitor, targets G12A specifically
• MRTX1133 (Mirati Therapeutics) — primarily G12D, but may have activity against G12A

Source: NCCN Guidelines for Patients: Ovarian Cancer (2025) — biomarker testing section; Cancer Patient Lab webinars on precision medicine

---

BRAF Mutation: Gly469Ala (G469A)

What it means:

• Your cancer also has a BRAF mutation (different from KRAS)
• BRAF mutations are found in 5-10% of ovarian cancers
• This mutation can drive cancer growth independently or in combination with KRAS

Treatment implications:

• ⚠️ BRAF mutations can confer resistance to some therapies
• ⚠️ BRAF + KRAS co-mutations may require combination targeted therapy
• ✅ BRAF inhibitors (dabrafenib + trametinib) are FDA-approved for BRAF-mutant cancers
• ⚠️ Limited data on BRAF inhibitors in ovarian cancer; more commonly used in melanoma

Clinical trial options:

• Some KRAS inhibitor trials may include BRAF-mutant patients
• BRAF inhibitor trials may be available (less common for ovarian cancer)
• Combination KRAS + BRAF inhibitor therapy is being explored in clinical trials

Source: NCCN Guidelines for Patients: Ovarian Cancer (2025) — biomarker testing; Cancer Patient Lab webinars on multi-mutation cancers

---

HRD/HRP Status: NEGATIVE (HRP — Homologous Recombination Proficient)

What it means:

• Your cancer does NOT have homologous recombination deficiency (HRD)
• Your cancer is "HRP" — homologous recombination proficient
• This means your cancer cells can repair DNA damage efficiently
• HRD-negative status is associated with PARP inhibitor resistance

Treatment implications:

• ❌ PARP inhibitors (niraparib, olaparib, rucaparib) are less effective in HRD-negative cancers
• ✅ KRAS inhibitors may be more effective than PARP inhibitors for your cancer
• ⚠️ Niraparib is still an option, but response rates are lower in HRD-negative patients
• ✅ Bevacizumab (which you already received) is effective in HRD-negative cancers

Clinical trial options:

• KRAS inhibitor trials are particularly important for HRD-negative patients
• Combination KRAS inhibitor + bevacizumab trials may be available
• Immunotherapy trials may be relevant (if your tumor has high TMB or MSI)

Source: NCCN Guidelines for Patients: Ovarian Cancer (2025) — maintenance therapy section; Cancer Patient Lab webinars on precision medicine

---

BRCA Status: NEGATIVE

What it means:

• You do NOT have a BRCA1 or BRCA2 mutation (germline or somatic)
• Your cancer is not BRCA-associated
• This confirms your HRD-negative status (BRCA mutations are a form of HRD)

Treatment implications:

• ❌ BRCA-targeted therapies are not applicable
• ✅ Confirms that KRAS inhibitors are more appropriate than PARP inhibitors
• ✅ You are not at increased hereditary cancer risk (unless other genetic factors present)

Source: NCCN Guidelines for Patients: Ovarian Cancer (2025) — genetic testing section

---

ER/PR/HER2 Status: ALL NEGATIVE

What it means:

• Your cancer is NOT estrogen receptor (ER) positive
• Your cancer is NOT progesterone receptor (PR) positive
• Your cancer is NOT HER2 positive
• This is typical for mesonephric-like adenocarcinoma

Treatment implications:

• ❌ Hormone therapy (tamoxifen, aromatase inhibitors) is not effective
• ❌ HER2-targeted therapy (trastuzumab/Herceptin) is not effective
• ✅ Chemotherapy, PARP inhibitors, KRAS inhibitors, and bevacizumab are appropriate

Source: NCCN Guidelines for Patients: Ovarian Cancer (2025) — biomarker testing section

---

Summary: What Your Biomarkers Tell Us

Your biomarker profile is UNIQUE and suggests precision medicine approach:

| Biomarker | Status | Treatment Implication | |-----------|--------|----------------------| | KRAS G12A | ✅ Positive (Pathogenic) | KRAS inhibitor trials are priority | | BRAF G469A | ✅ Positive | May require combination therapy; increases complexity | | HRD/HRP | ❌ Negative (HRP) | PARP inhibitors less effective; KRAS inhibitors more important | | BRCA | ❌ Negative | No BRCA-targeted therapy; no hereditary cancer risk | | ER/PR/HER2 | ❌ All Negative | No hormone therapy or HER2 therapy |

Bottom line: Your KRAS G12A mutation is the most actionable biomarker. KRAS inhibitor trials should be seriously considered as first-line maintenance therapy, rather than standard PARP inhibitors.

---

SECTION 2: YOUR TREATMENT HISTORY

Chemotherapy: Carboplatin/Paclitaxel (COMPLETED)

What you received:

• 6 cycles of carboplatin + paclitaxel (standard HGSC regimen)
• Given every 3 weeks (18 weeks total)
• Completed as of [your completion date]

Why this regimen:

• Platinum-based chemotherapy is standard first-line treatment for ovarian cancer
• Carboplatin is a platinum agent that damages cancer cell DNA
• Paclitaxel (Taxol) is a taxane that prevents cancer cell division
• Combination is highly effective for most ovarian cancers

Expected side effects (that you likely experienced):

• Nausea and vomiting
• Hair loss
• Fatigue
• Low blood counts (anemia, low platelets, low white blood cells)
• Nerve damage (peripheral neuropathy) — numbness/tingling in hands/feet
• Mouth sores
• Increased infection risk

Your response:

• You tolerated 6 cycles (completed full course)
• Lesions detected by end of November (suggests partial response or stable disease)
• Eligible for maintenance therapy (indicating cancer did not progress during chemo)

Source: NCCN Guidelines for Patients: Ovarian Cancer (2025) — chemotherapy section

---

Bevacizumab (Avastin): 22 Treatments (COMPLETED)

What you received:

• 22 infusions of bevacizumab (15 mg/kg IV)
• Given concurrently with chemotherapy and continued after
• Completed as of [your completion date]

Why bevacizumab:

• Bevacizumab is an anti-angiogenic drug (stops new blood vessel formation)
• Starves tumors of blood supply, slowing growth
• Improves survival when added to chemotherapy in ovarian cancer
• Particularly effective in HRD-negative cancers (like yours)

Expected side effects (that you likely experienced):

• High blood pressure
• Proteinuria (protein in urine)
• Bleeding risk (nosebleeds, blood in urine)
• Wound healing problems
• Fatigue
• Headache

Your response:

• You tolerated 22 treatments (completed full course)
• Bevacizumab is continued as maintenance therapy (see below)

Source: NCCN Guidelines for Patients: Ovarian Cancer (2025) — chemotherapy and maintenance therapy sections

---

Current Status: Post-Chemotherapy, Pre-Maintenance Therapy

Timeline:

• Last chemotherapy: [Your completion date]
• Current date: [Today]
• Time since chemo: [X weeks/months]

What's happening now:

• Your bone marrow is recovering from chemotherapy
• Blood counts are normalizing
• Side effects from chemo are resolving
• You're preparing to start maintenance therapy

Blood count recovery timeline:

• Week 1-2 after chemo: Blood counts at lowest (nadir)
• Week 2-3: Counts begin recovering
• Week 3-4: Counts reach safe levels for next treatment
• Week 4+: Counts stable; ready for maintenance therapy

Source: NCCN Guidelines for Patients: Ovarian Cancer (2025) — chemotherapy section

---

SECTION 3: MAINTENANCE THERAPY OPTIONS

Standard-of-Care Maintenance Therapy

Option 1: PARP Inhibitor Monotherapy (Niraparib, Olaparib, or Rucaparib)

What it is:

• PARP inhibitors are oral targeted therapies that block DNA repair
• Taken as daily pills at home
• Continued for 2 years or until disease progression

NCCN Recommendation (2025): "For HRD-negative cancers, PARP inhibitor monotherapy is an option, though response rates are lower than in HRD-positive cancers."

Specific PARP inhibitors:

Niraparib (Zejula)

• Dose: 300 mg once daily (or 200 mg, 100 mg if dose reduction needed)
• Monitoring: Blood tests every 1-2 weeks for first 4-6 weeks, then every 4-8 weeks
• Side effects: Anemia (70-80%), low platelets (30-40%), nausea (30-40%), fatigue (50-60%)
• Duration: 2 years or until progression
• Your status: Likely prescribed (mentioned in your medical profile)

Olaparib (Lynparza)

• Dose: 300 mg twice daily
• Monitoring: Similar to niraparib
• Side effects: Similar to niraparib
• Duration: 2 years or until progression
• Your status: Alternative option if niraparib not tolerated

Rucaparib (Rubraca)

• Dose: 600 mg twice daily
• Monitoring: Similar to niraparib
• Side effects: Similar to niraparib
• Duration: 2 years or until progression
• Your status: Mentioned as option in your medical profile

Effectiveness in HRD-negative cancers:

• Response rate: 20-30% (lower than HRD-positive cancers at 50-60%)
• Median progression-free survival: 6-9 months (vs. 12-18 months in HRD-positive)
• ⚠️ Limited benefit compared to observation alone in some HRD-negative patients

Pros:

• ✅ FDA-approved for ovarian cancer
• ✅ Oral medication (no infusions)
• ✅ Well-tolerated in most patients
• ✅ Can be taken at home

Cons:

• ❌ Lower effectiveness in HRD-negative cancers (like yours)
• ❌ Requires intensive monitoring first 4-6 weeks
• ❌ Common side effects (anemia, low platelets)
• ❌ May not be optimal for KRAS-mutant cancers

Source: NCCN Guidelines for Patients: Ovarian Cancer (2025) — maintenance therapy section

---

Option 2: Bevacizumab Monotherapy (Avastin)

What it is:

• Continuation of bevacizumab (which you already received during chemo)
• Given as IV infusion every 2-3 weeks
• Continued for 15 months (or until progression)

NCCN Recommendation (2025): "Bevacizumab monotherapy is an option for maintenance therapy, particularly in HRD-negative cancers."

**